418 related articles for article (PubMed ID: 9815853)
41. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
Xu FJ; Boyer CM; Bae DS; Wu S; Greenwald M; O'Briant K; Yu YH; Mills GB; Bast RC
Int J Cancer; 1994 Oct; 59(2):242-7. PubMed ID: 7927925
[TBL] [Abstract][Full Text] [Related]
42. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.
Hijazi MM; Thompson EW; Tang C; Coopman P; Torri JA; Yang D; Mueller SC; Lupu R
Int J Oncol; 2000 Oct; 17(4):629-41. PubMed ID: 10995872
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
Yu D; Liu B; Tan M; Li J; Wang SS; Hung MC
Oncogene; 1996 Sep; 13(6):1359-65. PubMed ID: 8808711
[TBL] [Abstract][Full Text] [Related]
44. Altered expression of integrins in adriamycin-resistant human breast cancer cells.
Narita T; Kimura N; Sato M; Matsuura N; Kannagi R
Anticancer Res; 1998; 18(1A):257-62. PubMed ID: 9568087
[TBL] [Abstract][Full Text] [Related]
45. Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells.
Li W; Park JW; Nuijens A; Sliwkowski MX; Keller GA
Oncogene; 1996 Jun; 12(11):2473-7. PubMed ID: 8649790
[TBL] [Abstract][Full Text] [Related]
46. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
Yuste L; Montero JC; EsparÃs-Ogando A; Pandiella A
Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
[TBL] [Abstract][Full Text] [Related]
47. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40.
Furger C; Fiddes RJ; Quinn DI; Bova RJ; Daly RJ; Sutherland RL
Cancer Res; 1998 May; 58(9):1773-8. PubMed ID: 9581810
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
Brysch W; Magal E; Louis JC; Kunst M; Klinger I; Schlingensiepen R; Schlingensiepen KH
Cancer Gene Ther; 1994 Jun; 1(2):99-105. PubMed ID: 7621247
[TBL] [Abstract][Full Text] [Related]
49. ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires MMP-13 and uPA upregulation via p38 MAPK signaling.
Yong HY; Kim IY; Kim JS; Moon A
Int J Oncol; 2010 Feb; 36(2):501-7. PubMed ID: 20043086
[TBL] [Abstract][Full Text] [Related]
50. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
Roh H; Pippin J; Boswell C; Drebin JA
J Surg Res; 1998 Jun; 77(1):85-90. PubMed ID: 9698539
[TBL] [Abstract][Full Text] [Related]
51. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.
Le XF; McWatters A; Wiener J; Wu JY; Mills GB; Bast RC
Clin Cancer Res; 2000 Jan; 6(1):260-70. PubMed ID: 10656457
[TBL] [Abstract][Full Text] [Related]
52. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
53. Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation.
Rivas MA; Tkach M; Beguelin W; Proietti CJ; Rosemblit C; Charreau EH; Elizalde PV; Schillaci R
Breast Cancer Res Treat; 2010 Jul; 122(1):111-24. PubMed ID: 19760502
[TBL] [Abstract][Full Text] [Related]
54. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
Zhang L; Chang CJ; Bacus SS; Hung MC
Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
[TBL] [Abstract][Full Text] [Related]
55. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
Ishizawar RC; Miyake T; Parsons SJ
Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
[TBL] [Abstract][Full Text] [Related]
56. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
[TBL] [Abstract][Full Text] [Related]
57. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
Xu F; Lupu R; Rodriguez GC; Whitaker RS; Boente MP; Berchuck A; Yu Y; DeSombre KA; Boyer CM; Bast RC
Int J Cancer; 1993 Feb; 53(3):401-8. PubMed ID: 7679090
[TBL] [Abstract][Full Text] [Related]
58. Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput Kinase receptor activation enzyme-linked immunosorbant assay.
Sadick MD; Sliwkowski MX; Nuijens A; Bald L; Chiang N; Lofgren JA; Wong WL
Anal Biochem; 1996 Mar; 235(2):207-14. PubMed ID: 8833330
[TBL] [Abstract][Full Text] [Related]
59. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
60. Copine-III interacts with ErbB2 and promotes tumor cell migration.
Heinrich C; Keller C; Boulay A; Vecchi M; Bianchi M; Sack R; Lienhard S; Duss S; Hofsteenge J; Hynes NE
Oncogene; 2010 Mar; 29(11):1598-610. PubMed ID: 20010870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
